---
schema_version: "secwatch.filing_event.v1"
accession: "0001562762-25-000032"
form_type: "8-K"
ticker: "CHE"
cik: "0000019584"
company_name: "CHEMED CORP"
filed_at: "2025-02-26T23:59:59+00:00"
generated_at: "2026-05-26T04:00:34.781445+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Chemed Q4 2024 revenue up 9.2% to $640M; adj. EPS $6.83; guides FY2025 adj. EPS $24.95-$25.45

## Summary
- GAAP diluted EPS $6.02 (+2.0% YoY); adjusted diluted EPS $6.83 (+3.5% YoY).
- VITAS net patient revenue $411M (+17.4% YoY); ADC 22,179 (+14.6%).
- Roto-Rooter revenue $229M (-2.9% YoY); adjusted EBITDA margin 26.3% (-120 bps).
- FY2025 guidance: VITAS revenue growth 10.5%-11.3%, Roto-Rooter revenue growth 2.4%-3.0%.
- No debt; $178.4M cash; repurchased 388,235 shares for $212.8M at $548.13/share.

## SEC filing metadata
- accession: 0001562762-25-000032
- form_type: 8-K
- ticker: CHE
- cik: 0000019584
- company_name: CHEMED CORP
- filed_at: 2025-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/19584/000156276225000032/0001562762-25-000032-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/19584/000156276225000032/che-20250226x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001562762-25-000032
- JSON: https://secwatch.observer/filing/0001562762-25-000032.json
- Plain text: https://secwatch.observer/filing/0001562762-25-000032.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.